Human HIV integrase inhibitors are a novel class of antiretroviral drugs that act by blocking incorporation of the proviral DNA into the host cell genome, a crucial step in the life cycle of HIV. In the present work, quantitative methods for prediction of human pharmacokinetics were used to guide the selection of development candidates from a series of dihydroxypyrimidine and N-methylpyrimidinone carboxamide inhibitors of HIV integrase, which are cleared mainly by O-glucuronidation. The pharmacokinetics of 10 drugs from this series was determined in several preclinical species, including rats, dogs, rhesus monkeys, and rabbits, and the in vitro turnover, plasma protein binding, and blood/plasma partition ratio were studied using preparations from both preclinical species and humans. Two clearance prediction methods, based on physiologically based scaling or allometric scaling normalized for differences in microsomal turnover, were used to extrapolate human clearance. For three clinical candidates, including the novel AIDS drug raltegravir (MK-0518, Isentress), oral drug exposure was predicted and compared with that observed in healthy human volunteers. Both scaling methods gave a reasonable correspondence between predicted and observed oral exposure. Prediction errors for the physiologically based method were less than 1.7-fold for two drugs, including raltegravir, and less than 3.5-fold for one drug. The exposures predicted using normalized allometric scaling were within 1.1-to 1.5-fold of observed values for all three compounds. The accuracy of prediction by normalized allometric scaling was similar when using data from either four preclinical species or from rats and dogs only. The prediction methods used may be applicable to other drugs cleared predominantly by glucuronidation.
HIV-1 is responsible for AIDS, one of the most urgent world health threats. Currently approved therapies are based on inhibitors of HIV protease, reverse transcriptase, and viral entry (De Clercq, 2005) . The combination of three or more drugs from two or more available classes (highly active antiretroviral therapy) has demonstrated efficacy in strongly reducing morbidity and mortality, but because of the rapid emergence of drug-resistant viral strains and the toxicities associated with chronic treatment, there is a critical need for new HIV therapies. HIV-1 integrase, which catalyzes the incorporation of the viral DNA into the host cell genome, is an appealing new drug target because of its essential function in viral replication and the absence of a direct counterpart in the host cells (Hazuda et al., 1997; Young, 2001) . We recently described a series of dihydroxypyrimidine and N-methylpyrimidinone carboxamide inhibitors of HIV integrase (Summa et al., 2006; Gardelli et al., 2007; Pace et al., 2007; Petrocchi et al., 2007; Muraglia et al., 2008) . The purpose of the present study was to select a drug with potentially favorable human pharmacokinetic (PK) properties among potent lead compounds from this chemical series.
The currently used approaches for predicting human clearance of drugs fall into three major classes, physiologically based scaling (PBS) models, allometric scaling, and allometric scaling of in vivo clearance normalized by in vitro clearance data [normalized allometric scaling (NAS)]. In the PBS method, in vitro turnover in liver microsomes or hepatocytes is used to estimate intrinsic clearance for the whole liver by the use of a scaling factor and, subsequently, hepatic clearance (CL h ) with the use of a physiologic liver model (Obach et al., 1997; Ito et al., 1998; Lin, 1998; Riley et al., 2005) . Allometric scaling is an alternative method to extrapolate human pharmacokinetic parameters from animal data. This method is based on the principle that organ size, regional blood flow, and body weight of mammals are characterized empirically by a simple power law expression and that xenobiotic clearance may be related directly to the physiological variables (Tang and Mayersohn, 2006) . Although allometric scaling of pharmacokinetic parameters, such as clearance, has been successful for many drugs, it is generally believed that the method is not appropriate for compounds whose clearance is limited by their intrinsic rates of metabolism, which is determined by speciesand drug-specific biochemical parameters. Lave et al. (1997) showed that normalizing the in vivo clearance in different animal species for the relative rates of metabolism in vitro (NAS method) dramatically improved the predictions of human clearance of 10 extensively metabolized drugs compared with the approach in which clearance is directly extrapolated using body weight. Physiologically based methods were found to be superior to allometric approaches in predicting human clearance of 33 drugs from various structural and therapeutic classes (Ito and Houston, 2005) . However, they have had limited success in predicting the clearance of drugs that are mainly metabolized by glucuronidation (Lin and Wong, 2002; Miners et al., 2006) .
The pharmacokinetics of 10 investigational HIV integrase inhibitors was determined in several preclinical species, and the in vitro turnover, plasma protein binding, and blood/plasma partition ratio were studied using preparations from both preclinical species and humans. Two different clearance prediction methods, PBS and NAS, were used to extrapolate human clearance and to guide the selection of compounds with appropriate potency and predicted human PK properties. One of these novel anti-HIV drugs, raltegravir, demonstrated robust antiviral activity in treatment-naive patients and in HIV-1 patients with triple-class resistance and has been approved recently for the treatment of AIDS (Evering and Markowitz, 2007) .
Materials and Methods
Reagents. HIV integrase inhibitors were synthesized at the Istituto di Ricerche di Biologia Molecolare P. Angeletti (IRBM)-Merck Research Laboratories Rome. Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and were of the highest purity available. Human liver microsomes (pooled from 22 donors), rat liver microsomes (pooled from 10 male SpragueDawley rats), and dog liver microsomes (pooled from eight male beagle dogs) were purchased from BD Gentest (Woburn, MA). Rhesus monkey liver microsomes (pooled from eight male monkeys) were obtained from XenoTech, LLC (Lenexa, KS). Rabbit liver microsomes were prepared using standard procedures (Di Marco et al., 2003) . Rat plasma (pooled from 10 male SpragueDawley rats) was purchased from Charles River Italica (Calco, Italy), and dog plasma (pooled from 10 male beagle dogs) was from Harlan (Indianapolis, IN). Rhesus monkey and rabbit plasma (pooled from three donors) were prepared at Merck Research Laboratories. Normal human plasma was obtained from the Italian Red Cross (Rome, Italy).
Animals. Male Sprague-Dawley rats weighing 250 to 300 g (Charles River Italica), New Zealand white rabbits weighing 2 to 3 kg (Charles River Italica), male beagle dogs weighing 7 to 10 kg (Marshall-Green Hill Montichiari, Brescia, Italy), and male rhesus monkeys (Macaca mulatta) weighing 3 to 5 kg (RC Hartelust BV, Tilburg, The Netherlands) were used for in vivo studies. Animals were maintained under a 12-h light/dark cycle with free access to food and water. The animals were housed and handled in compliance with European Union directive 86/609/EEC and Italian law DL 116/92 for the protection of vertebrate animals used for experimental and other scientific purposes. All animal studies were reviewed and approved by the IRBM Institutional Animal Care and Use Committee and the Italian Ministry of Health.
In Vivo Pharmacokinetic Studies. For pharmacokinetic studies, animals were fasted overnight before dosing and housed individually. Plasma samples from PK studies were stored frozen until analysis by liquid chromatography (LC) coupled with tandem mass spectrometry detection (MS/MS), as described below.
Rat Studies. One day before the experiment, in-dwelling jugular vein cannulae were implanted under ketamine-xylazine anesthesia. Three animals received an intravenous bolus dose of each drug [3 mg/kg, dissolved in DMSO/PEG400/water, 20:60:20 (v/v); 0.5 ml/kg] via the tail vein. Three animals received oral doses of drug, dissolved in 1% methylcellulose, via a gavage needle. Blood samples were drawn at various times from the jugular vein cannula into heparinized tubes, and plasma was prepared by centrifugation.
Rabbit Studies. Three animals received an intravenous bolus dose of each drug [1 mg/kg, dissolved in DMSO/PEG400/water, 20:60:20 (v/v); 0.5 ml/kg] via the marginal vein of the ear. Blood samples (0.4 ml) were collected from the ear vein into heparinized tubes, and plasma was prepared.
Dog and Monkey Studies. Three animals received an intravenous dose of each drug [0.6 -1 mg/kg, dissolved in DMSO/PEG400/water, 20:60:20 (v/v); 0.5 ml/kg] via the cephalic vein (dogs) or saphenous vein (monkeys). Three dogs received an oral dose of drug (10 mg/kg, dissolved in 1% methylcellulose) via a gavage tube. Blood samples were drawn at various times from the jugular vein into heparinized tubes, and plasma was prepared.
Plasma Protein Binding. Plasma was spiked with test drug to yield a final concentration of 10 M. After incubation at 37°C for 1 h, an aliquot was transferred to an ultrafiltration device (Millipore Corporation, Billerica, MA), which was centrifuged at 1500g for 1 h at 37°C. Samples were analyzed by LC-MS/MS. The concentrations of drug in the filtrate were compared with those of a standard curve containing known amounts of drug dissolved in plasma, from which proteins had been removed by ultrafiltration. The unbound fraction was estimated from the ratio of drug concentration in the filtrate to that in the original plasma samples. Parallel studies using protein-free plasma instead of plasma indicated that test drugs were bound minimally to the ultrafiltration device.
Blood-Plasma Partition. Compounds were added to whole blood or plasma to obtain final concentrations of 10 M and incubated at 37°C for 30 min. Plasma was separated from blood samples and analyzed by LC-MS/MS. The blood/plasma concentration ratio (BP) was determined by dividing the total initial concentration in blood by that found in plasma separated from blood samples.
The theoretical BP ratio was also calculated assuming partition is determined solely by plasma protein binding, according to the equation (Rowland and Tozer, 1995) :
where f u is the fraction of unbound drug in plasma, and H is the hematocrit (rat, 0.46; dog, 0.42; monkey, 0.41; rabbit, 0.36; human, 0.44) (Davies and Morris, 1993) . Drug Turnover in Liver Microsomes. All incubations were conducted in duplicate using 1 mg/ml microsomal protein and 1 M test drugs, in the presence of either NADPH or UDPGA. Incubations to assess oxidative metabolism included 3.3 mM MgCl 2 , 1.0 mM NADP, 2.5 mM glucose 6-phosphate, 2 U/ml glucose 6-phosphate dehydrogenase, and 0.1 M potassium phosphate buffer, pH 7.4. Incubations to assess conjugative metabolism included 5 mM UDPGA, 5 mM D-saccharic acid 1,4-lactone, 2 mM MgCl 2 , 0.05 mg/ml alamethicin, and 0.1 M Tris-HCl, pH 7.4. Reactions were terminated after five different time intervals, typically 0, 10, 30, 60, and 90 min, by adding 1 volume of ice-cold acetonitrile containing 1 M internal analytical standard. The samples were centrifuged for 10 min at 4400g to pellet proteins, and the supernatant was subjected to LC-MS/MS analysis as described below.
For determination of CL in , drug concentrations determined after different times of incubation with microsomes were expressed as a percentage of drug remaining, using the t ϭ 0 min concentration value as 100%. CL in was calculated according to eq. 2:
where Dose is the initial amount of drug in the incubation mixture (unit of moles per milligram of microsomal protein), and AUC ϱ is the area under the concentration versus time curve, extrapolated to infinity (unit of molar per minute). The unit for CL in is liters per minute per milligram of protein. First order decline was observed for all drugs usually for up to 30 to 60 min and for up to 90 min for compounds with very low turnover. CL in was constant for drug concentrations up to 10 M and microsome concentrations up to 1 mg/ml, indicating lack of enzyme saturation and nonspecific microsome binding, respectively, under these experimental conditions (data not shown). Lack of microsome binding was confirmed by incubating drugs with microsomes followed by ultrafiltration and analysis of the free fraction (data not shown).
Drug Turnover in Hepatocytes. Hepatocytes were isolated from male Sprague-Dawley rats or human liver samples or obtained from commercial sources, as described previously (Giuliano et al., 2005) . Hepatocytes were suspended in hepatocyte culture medium at a density of 1 million cells/ml and incubated with drugs (1 M) in a shaking water bath at 37°C, under an atmosphere of 95% O 2 /5% CO 2 . Aliquots of cell suspension were removed after 0, 15, 30, 60, 120, 180 , and 240 min and deproteinized by addition of an equal volume of 0.1% formic acid in acetonitrile, followed by centrifugation at 3500g for 10 min and solid phase extraction (Giuliano et al., 2005) . Remaining drug was quantified by LC-MS/MS analysis.
Quantitative Analysis. Drug concentrations in plasma and in vitro incubations were determined by LC-MS/MS, using an Agilent 1100 series gradient high-performance liquid chromatography pump (Agilent Technologies, Santa Clara, CA), and a CTC HTS PAL autosampler (CTC Analytics, Zwingen, Switzerland) coupled to an Applied Biosystems/Sciex API 3000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) equipped with a turbo ion spray interface operated in positive ion mode. Plasma samples were deproteinized by acetonitrile precipitation, centrifuged, and the supernatant was dried under nitrogen. The samples were reconstituted in water/ acetonitrile [90:10 (v/v)] before analysis.
Chromatographic separation was performed with a Waters XTerra C18 5-m 50-ϫ 4.6-mm column (Waters, Milford, MA) eluted with a gradient of solvents A and B. Mobile phase A consisted of 0.1% formic acid in water and mobile phase B 0.1% formic acid in acetonitrile. Mobile phase B was ramped up from 5 to 95% between 0.0 and 2.0 min and was maintained at this concentration from 2.0 to 3.0 min, followed by a reduction from 95 to 5% between 3.0 and 3.1 min. Mobile phase B was maintained at 5% from 3.1 to 4.6 min. The flow rate for was set at 2.0 ml/min, and the injection volume was 10 l. The column eluent was diverted to waste for the first 0.5 min, and from 0.5 to 4.0 min, it was diverted into the ion source. Approximately 10% of the eluent was introduced into the mass spectrometer. The probe temperature was set at 450°C, and ion spray voltage was set at 5500 V. The instrument was set up to optimize the mass spectral lens settings for each of the analytes using a multiple-reaction monitoring-type optimization method, using as transition ions the pseudomolecolar ion (MϩH) and the more stable characteristic fragment (see Supplemental Table 1 ). Dwell times were set to 100 ms for each transition to provide a minimum of 10 data points across each peak. Quantitation was achieved by comparison of the analyte/internal standard peak area ratios with those of a calibration curve ranging from 0.305 to 5000 ng/ml (which corresponded to the dynamic range). Analyte concentrations were determined by weighted linear least-squares regression analysis, using Analyst software version 1.4 (Applied Biosystems).
Pharmacokinetic Analysis. Plasma clearance (CL P ) was calculated as the intravenous dose divided by the area under the plasma concentration-time curve (AUC) from zero to infinity. Oral bioavailability (F) was estimated as the AUC ratio after oral and intravenous administration normalized for differences in dose.
Clearance Prediction by in Vitro-in Vivo PBS. In vivo clearance was calculated according to the well stirred liver model (Wilkinson, 1987) :
where CL h is the hepatic clearance, Q is the hepatic blood flow (milliliters per minute per kilogram), f u is the free fraction of drug in plasma, BP is the blood/plasma partition ratio, and CL in_liver is the intrinsic hepatic clearance.
To scale up CL in_invitro , the intrinsic clearance in hepatic microsomes (units of milliliters per minute per milligram of microsomal protein), to whole-organ intrinsic clearance (CL in_liver , units of milliliter per minute per kilogram of body weight), the following scaling factors were used: microsomal protein yield per gram of liver: human, 32 mg/g (Barter et al., 2007) ; and other species, 45 mg/g; and liver weight (g/kg body weight) : rat, 40; dog, 33; monkey, 30; rabbit, 31; and human, 26 . The values used for liver blood flow (milliliters per minute per kilogram) were as follows : rat, 70; dog, 40; monkey, 45; rabbit, 44; and human, 20 (Boxenbaum, 1980; Davies and Morris, 1993; Lin et al., 1996) .
The predicted plasma clearance CL P was then calculated assuming that drugs are cleared exclusively by hepatic metabolism:
Clearance Prediction by NAS. Equation 3 was rearranged to calculate intrinsic in vivo clearance (CL in_invivo ):
assuming that clearance occurs exclusively in the liver, i.e., CL in_invivo ϭ CL in_liver . The observed CL in_invivo for each species was correlated with the respective body weight according to an allometric relationship, applying a normalization factor for differences in in vitro (microsomal) intrinsic clearance (Lave et al., 1997) :
where CL in_liver_human and CL in_liver_animal are the whole-organ intrinsic clearance values calculated from human and animal liver microsomal incubations, respectively, using the scaling factors described in the preceding section; and W is the average body weight: rat, 0.25 kg; dog, 8.2 kg; monkey, 5.0 kg; rabbit, 3.0 kg; and human, 70 kg.
Plots of: 
where Dose is the amount of orally administered drug (micromoles per kilogram), CL P is the predicted human plasma clearance (milliliters per minute per kilogram), and F is the estimated oral bioavailability. The value used for F was the average bioavailability observed in preclinical species. For comparison, F was also calculated as the fraction of the dose escaping hepatic first-pass extraction, assuming plasma clearance is due to hepatic metabolism, complete intestinal absorption, and absence of gut extraction:
Results
The structures of the HIV integrase inhibitors investigated in the present study are shown in Table 1 , along with their antiviral potency, as assessed by the concentration required to inhibit viral spread in HIV-infected cells by 95% (CIC 95 ). Table 2 summarizes the values of the in vitro parameters used for prediction of hepatic clearance, namely intrinsic oxidative and glucuronidation clearance in liver microsomes, unbound fraction in plasma, and BP. Plasma protein binding was generally between 60 and 90%. For some drugs, important species differences were observed. For example, the unbound fraction of compound 10 ranged from 0.007 in rat to 0.16 in monkey ( Table 2 ). The BP was calculated according to eq. 1. For some drugs, BP was also determined experimentally and found to be similar to calculated values (see Table 2 ). Full experimental data for BP in all preclinical species and human were available for compounds 1 to 3 and were used for scaling analysis. [When the calculated value of BP was used for scaling analysis, values of human clearance by both prediction methods were close to those obtained using experimental BP values (Ͻ16% difference.] For the other drugs, calculated values of BP were used. None of the drugs studied exhibited significant binding to microsomal membranes (data not shown). For most of the drugs studied, the rate of metabolism in hepatic microsomes from preclinical species was higher in the presence of the cofactor UDPGA than in the presence of NADPH. In human liver microsomes, the rate of glucuronidation clearance was higher than that of oxidative clearance for all drugs examined. Compounds 1 to 10 contain a dihydroxypyrimidine or hydroxypyrimidinone core structure, which is subject to 5-O-glucuronidation by UDP glucuronosyltransferase (UGT) enzymes (Summa et al., 2006; Gardelli et al., 2007; Monteagudo et al., 2007; Muraglia et al., 2008) . For all compounds, the lowest rate of metabolism was observed in human and dog liver microsomes (Table 2) .
Metabolic turnover of selected integrase inhibitors was also assessed in intact rat and human hepatocytes. As shown in Supplemental Table 2 , drugs were more stable in human than in rat hepatocytes, in agreement with the relative turnover observed in microsomal preparations. Intrinsic clearance in hepatocytes from both species was generally substantially lower than total (glucuronidation ϩ oxidation) clearance in liver microsomes, considering that 1 million cells contain 0.3 to 0.5 mg of microsomal protein. The cells used displayed high turnover of the typical UGT substrate 4-methylumbelliferone, with maximal glucuronidation activity greater than 100 pmol/min/million cells. The cells also displayed good testosterone 6␤-hydroxylase activity, a measure of oxidative, cytochrome P450 3A-mediated metabolism (see Supplemental Table 2 ).
Hepatic clearance was scaled up from the microsomal clearance using the PBS method according to eq. 3 and compared with the observed in vivo clearance in preclinical species (see Table 3 ). The ratio between observed and predicted clearance is denoted O/P (Table  3 ; Fig. 1 ). With few exceptions (such as compounds 5 and 7), O/P values were greater than 2 in most species, indicating that scaling according to the physiological model leads to underprediction of systemic clearance. Furthermore, O/P values varied greatly between different drugs in the same species (e.g., over a 10-fold range in both rats and dogs) and, in some cases, for the same drug between different species (e.g., 2 and 8 for compound 9 in monkey and dog, respectively; see Fig. 1 ). To obtain a corrected estimate of human clearance, the scaled (predicted) human CL h for each drug was multiplied by O/P for each preclinical species. The range of estimated human plasma clearance thus obtained is summarized in Table 3 . Although relatively narrow ranges were obtained for most drugs (approximately 2-fold difference between upper and lower bounds), the range of predicted human clearance was relatively broad for compounds 8 to 10, with 3-to 4-fold differences between upper and lower limits.
Human clearance was also predicted using NAS, an allometric method corrected for species differences in intrinsic metabolic clearance (Lave et al., 1997) . CL in_invivo in preclinical species was derived from the observed plasma clearance, the unbound fraction in plasma, and the BP partition ratio. The normalization factor R represents the ratio of CL in_invitro observed in human versus animal liver microsomes. For all compounds examined, linear regression analysis of [log(CL in_invivo ) ϫ R] against the logarithm of body weight (logW) displayed correlation coefficients (r 2 ) between 0.93 and 0.99 (see Table 4 ). Typical curves are shown in Fig. 2 for compounds 1 to 3. Human CL in_invivo was extrapolated from these plots and used to project human plasma clearance. The NAS method was also used to predict human plasma clearance on the basis of rat and dog data only (see Table 4 ).
Compound 1 was the first HIV integrase inhibitor from this series that was selected as a candidate for development of a drug for the treatment of AIDS. The search for additional inhibitors with improved properties was driven mainly by antiviral potency in vitro and human clearance predicted by the NAS method. A score equal to the product 
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at ASPET Journals on April 8, 2017 dmd.aspetjournals.org of CIC 95 and predicted CL P , which should be as low as possible, was used to rank compounds. The scores for compounds 1 to 10 were 363, 115, 56, 186, 427, 124, 308, 214, 76, and 86 . Thus, five drugs were identified (compounds 2, 3, 6, 9, and 10), which had scores that were comparable (between 50 and 120) and at least 3-fold better than compound 1. Among these, compounds 2 and 3 were chosen as development candidates on the basis of additional criteria, such as physicochemical characteristics, lack of toxicological liabilities, oral absorption, ease of synthesis, etc.
The oral pharmacokinetic properties of the three candidate drugs in preclinical species are summarized in Supplemental Table 3 . They were rapidly absorbed from the gastrointestinal tract, with good oral bioavailability in both rats and dogs. To predict exposures in humans upon oral dosing, the average oral bioavailability observed in rats and dogs was used as an estimate of human oral bioavailability, 65 Ϯ 29, 66 Ϯ 4, and 63 Ϯ 2% for compounds 1 to 3, respectively (mean Ϯ half-range). For comparison, human oral bioavailability was also calculated based on predicted hepatic extraction according to eq. 8, using the predicted values of CL h and assuming that drugs are eliminated by hepatic metabolism, that absorption is complete, and that there is no first-pass extraction in the gut. The first assumption is supported by the finding that renal or biliary excretion of intact drug accounted for less than 15% of total clearance in rats and dogs (data not shown). Human oral bioavailability estimated by this method was 65, 68, and 71% for compounds 1 to 3, respectively, which is very close to the average bioavailability in rats and dogs.
The predicted human oral plasma AUC was then calculated according to eq. 7, using the human plasma clearance predicted by the different scaling methods along with estimated oral bioavailability, and compared with the oral exposures observed in clinical studies. The pharmacokinetics of compound 2 (raltegravir) in healthy human subjects has been described recently (Iwamoto et al., 2008) . Similarly to compound 2, compounds 1 and 3 were rapidly absorbed after an oral dose of 200 mg, with C max of 7.3 and 3.3 M and T max of 0.8 and 1.4 h, respectively. The decline from the peak plasma concentration followed biphasic kinetics with a terminal half-life of approximately 10 h. The values of predicted human AUC for a 200-mg oral dose of compounds 1 to 3 and those observed in healthy human volunteers are summarized in Table 5 . The upper and lower limits of the range of AUC values predicted by the PBS method differed by approximately 2-fold for each of the three drugs. The AUC observed in healthy human volunteers fell within the predicted range only for compound 2. The observed AUC was very close to the upper limit of predicted values for compound 1 (within 1.2-fold), but for compound 3, it was 1.6-fold lower than the closest estimate. Oral AUC values predicted using the NAS method were very close to the observed AUC, with c Ratio between observed and predicted plasma clearance. d Corrected predicted human CL P was calculated by multiplying predicted human CL P by O/P for each preclinical animal species. For example, predicted human CL P for compound 1 is 1.56 ml/min/kg. O/P for rat is 3.09. Thus, corrected predicted human CL P based on rat data is 4.8 ml/min/kg. Apparent discrepancies in products or ratios are due to rounding. dmd.aspetjournals.org 1.2-, 0.9-, and 0.7-fold error for compounds 1 to 3, respectively. Predictions according to the NAS method using only rat and dog data also gave a very good correspondence with observed AUC values, with Յ1.5-fold difference between observed and predicted values for all three drugs.
Discussion
The prediction of human pharmacokinetics of drug candidates is one of the most important objectives of preclinical drug metabolism studies. For drugs that are cleared predominantly through cytochrome P450-mediated oxidative metabolism, there is growing evidence that successful prediction of in vivo metabolic clearance from in vitro metabolic data can be achieved (Iwatsubo et al., 1996; Lin, 1998; Obach, 2001; Ito and Houston, 2005; Riley et al., 2005) . However, when glucuronidation makes an important contribution to metabolic clearance, in vitro data seem to correlate less well with the clearance observed in vivo. For the drugs analyzed in the present study, the noncorrected clearance values obtained from direct in vitro-in vivo scaling of hepatic microsomal clearance using the PBS model were significantly lower than the systemic clearance observed in preclinical species. Similar observations have been reported previously for drugs that are mainly eliminated by glucuronidation. Several explanations for this discrepancy have been proposed (Lin and Wong, 2002; Miners et al., 2006) , including latency of UGTs in microsomes, limited transport of drug substrates into microsomal vesicles, product inhibition, inhibition by fatty acids released during microsomal incubations (Rowland et al., 2008) , and contribution of extrahepatic glucuronidation (Soars et al., 2002) . It has been claimed that glucuronidation clearance in intact hepatocytes provides a better estimate of hepatic clearance than that determined in microsomal preparations (Soars et al., 2002 ). This was not true for several of the compounds analyzed in this study, including compounds 1 to 3 and 7 to 9, which were turned over more slowly in hepatocytes than in liver microsomes, even though the cells efficiently metabolized the standard UGT substrate 4-methylumbelliferone. The reason for low hepatocyte clearance of these drugs is currently unknown. Possible explanations include active drug transport from the cell interior back into the culture medium, e.g., by P-glycoprotein or multidrug resistance-associated protein transporters. It is interesting that the extent of underprediction of systemic clearance from in vitro-in vivo scaling of microsomal clearance (the O/P ratio) varied for a given drug between different species and for different drugs in the same species. For instance, O/P values for compounds 6 and 7 were high and low, respectively, in all species examined, whereas O/P for compounds 9 and 10 varied over a 4-fold range between different species (see Fig. 1 ). These results suggest that the discrepancies between in vitro and in vivo data are related to both compound-specific and physiologic differences rather than to a technical limitation of the in vitro system. Drugs from this series are substrates for enzymes of the human UGT1 family, including UGT1A1, UGT1A3, UGT1A8, and UGT1A9, with different relative activities for each compound (Kassahun et al., 2007; R. Laufer and E. Monteagudo, unpublished data) , suggesting that underprediction of clearance is not due to a specific UGT enzyme. A possible explanation for the underprediction of systemic clearance from scaling of hepatic microsomal clearance is that systemic clearance is the sum of hepatic and extrahepatic elimination. Although extrapolation of hepatic in vivo clearance may be accurate, this method cannot predict the contribution of extrahepatic elimination mechanisms. It is known that drugs can be glucuronidated in extrahepatic tissues, including the kidney, intestine, and skeletal muscle (Lin and Wong, 2002; Soars et al., 2002; R. Laufer and E. Monteagudo, unpublished data) . Renal glucuronidation clearance has been reported to contribute significantly to total clearance, being equal or higher than hepatic glucuronidation clearance for some drugs (Soars et al., 2002) . Extrahepatic glucuronidation may contribute to total drug elimination in a compound-and species-specific manner, depending on the kinetic parameters of metabolism of each drug by a specific UGT enzyme and the relative expression levels of UGT enzymes in different tissues.
Even when direct in vitro-in vivo scaling by PBS underpredicts systemic clearance, predicted values for human clearance can be corrected using the ratio (O/P) of observed versus predicted clearance in preclinical species. Ito and Houston (2005) , who described analogous approaches as empirical or drug-specific scaling, pointed out that although they provide an immediate pragmatic solution, in the longer term, it will be important to identify explanations and modify scaling strategies to account for systematic underprediction of clearance. It is obvious that if the O/P ratio is very variable among different species, a wide range of predicted human clearance will be obtained, which may be of limited practical value for selecting drugs with a high probability of displaying appropriate human pharmacokinetics. For most of the compounds analyzed in the present study, the range of predicted values for human clearance was reasonably narrow (approximately 2-fold difference between upper and lower limits), with the exception of compounds 8 to 10 (3-to 4-fold difference between upper and lower limits).
The NAS method provides an alternative approach to extrapolate human pharmacokinetic parameters from animal data. This method has been used to successfully predict the human hepatic clearance of 10 drugs that are extensively metabolized and represent a variety of metabolic pathways and a broad range of metabolic clearance in animals and man (Lave et al., 1997) . Because most of the studies that led to underprediction of in vivo glucuronidation clearance were based on physiologically based scaling of in vitro data, it was of interest to assess the performance of the NAS model. Linear relationships with correlation coefficients (r 2 ) ranging from 0.93 to 0.99 were obtained between corrected log(CL in_invivo ) values and log(body weight) in three (rat, dog, and monkey) or four (rat, dog, monkey, and rabbit) species. The allometric correlation coefficient is of limited value for judging accuracy of prediction . Nevertheless, for the three drugs that underwent human clinical pharmacokinetic studies, there was a good correspondence between predicted and observed oral AUC values, with less than 1.6-fold over-or underprediction. Although predictions of human AUC based on clearance estimates obtained by the NAS method seemed to be slightly more accurate than those obtained by PBS (in particular for compound 3), the differences between the 2 prediction methods were not statistically significant, given the limited data set.
For all compounds studied using NAS, there was very good agreement between clearance values predicted using data from only two preclinical species, rat and dog, and those obtained from three or four preclinical species (including monkey and rabbit). It is interesting that NAS using only rat and dog data gave an excellent correspondence (less than 15% error) between predicted and observed human oral AUC. Given the limited data set available, this correspondence may have been fortuitous, and for a drug candidate entering preclinical development, experiments in more than two species should be performed to gain confidence in predictions of human PK parameters. However, during the course of a drug discovery program, it may be sufficient to apply the NAS method to data obtained in the two most commonly used preclinical species, rat and dogs, to select promising compounds and to guide the design and optimization of lead molecules.
In addition to oral exposure, it is important to predict half-life from the preclinical data because these parameters will determine the dosing regimen. Because the pharmacokinetics of the drugs analyzed in the present study was multiphasic, with a relatively short ␣ phase and a long ␤ phase, simple allometric methods for prediction of volume of distribution could not be used to predict the pharmacologically relevant terminal half-life. Projections of the dose and dose interval required the generation of relatively complex simulation Table 3 ) and the estimated oral bioavailability, according to equation 7. S.E. values were calculated by propagation of the respective S.E. values.
b AUC observed in healthy human volunteers ( (Iwamoto et al., 2008 ; data on file, Merck Research Laboratories). Results are the mean Ϯ S.D. (n ϭ 6).
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Allometric scaling as a technique for predicting human pharmacokinetics has been controversial for a long time. It has been shown that the extrapolation of a power function established from animal species to human is a mathematically unfavorable procedure, dependent on data obtained in large animal species and subject to amplification of experimental errors (Tang and Mayersohn, 2005) . The NAS method corrects for differences in species-specific metabolism, but the inclusion of in vitro data into the scaling may further amplify errors. Alternative approaches, such as fixed-exponent allometry based on one or more species, have been proposed . Although we did not use these methods during the course of the drug discovery program described in the present article, it was of interest to assess their predictability post hoc. When data were analyzed using the rat-dog or rat-monkey fixed-exponent technique , either with or without correcting for in vitro metabolic differences, the prediction of human oral exposure for compounds 1 to 3 was less accurate than the NAS method, with predicted exposures between 2-and 20-fold higher than observed values (data not shown). We did not use more comprehensive prediction approaches based on physiologically based pharmacokinetic models, artificial neural networks (Parrott et al., 2005; Jones et al., 2006; De Buck et al., 2007a,b) , or pharmacokinetic simulation models (Wajima et al., 2004) because our focus was on a more streamlined and time-sparing approach suitable for supporting an early stage lead optimization program in screening mode.
Despite the widespread belief that it is problematic to quantitatively predict the human pharmacokinetic properties of drugs subject to conjugative metabolism, the current study provides an example of a successful in vitro-in vivo extrapolation strategy, which served to guide a medicinal chemistry program for the development of potent HIV integrase inhibitors for the treatment of AIDS. Among the three candidates, compound 2 (raltegravir) had the most appropriate combination of antiviral potency and pharmacokinetic properties, suitable for twice-daily dosing. Raltegravir has recently been approved as the first HIV integrase inhibitor for the treatment of AIDS (Evering and Markowitz, 2007) . The methods used, which rely on the systematic determination of hepatic microsomal turnover, plasma protein binding, and animal pharmacokinetics, may be applicable to other drugs cleared predominantly by glucuronidation.
